Pharmaceuticals, Biotechnology and Life Sciences
The U.S. Food and Drug Administration (FDA) has approved Darzalex (daratumumab) injection for intravenous infusion for the treatment of patients with multiple myeloma
A clinical trial funded by the National Institutes of Health has found that the drug ranibizumab (Lucentis) is highly effective in treating proliferative diabetic retinopathy.
The OSIRIS trial Phase II a investigating once daily OLYSIO (simeprevir) in combination with sofosbuvir in hepatitis C virus (HCV) genotype 4 infected patients, with and without liver cirrhosis, demonstrated treatment to be safe.
A Roche drug that can prolong the lives of some women with advanced breast cancer has been plunged back into the centre of a drug pricing row after Britain’s health cost agency declared that it is still too expensive.
A single dose of Bimatoprost Sustained-Release (SR) lowered intraocular pressure (IOP) in 92 percent (n= 69) of glaucoma patients at 4 months and 71 percent (n=53) at 6 months while demonstrating a favorable efficacy and safety profile.
The National Health Service (NHS) in England has more than doubled funding from £15m to £31m for its clinical pharmacists in general practice pilot, due to an overwhelmingly positive response from GP surgeries.
LEO Pharma and Japanese pharmaceutical company Astellas Pharma Inc. have entered into an Asset Purchase Agreement under which Astellas will transfer its global dermatology business to LEO Pharma for € 675 million.
US FDA has approved TAGRISSO for patients with EGFR T790M mutation-positive metastatic non-small cell lung cancer.
Dublin-based Horizon Pharma has provided an update on shareholders meeting related to the proposed acquisition of Depomed, Inc., according to which shareholders approved the issuance of up to 81,706,881 ordinary shares of Horizon Pharma plc, in connection with an acquisition of Depomed, Inc.
Novartis’ division and eye care specialist Alcon, is introducing its latest advancement in its WaveLightrefractive portfolio Contoura Vision.